BRPI0906020A2 - Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento - Google Patents

Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento

Info

Publication number
BRPI0906020A2
BRPI0906020A2 BRPI0906020-0A BRPI0906020A BRPI0906020A2 BR PI0906020 A2 BRPI0906020 A2 BR PI0906020A2 BR PI0906020 A BRPI0906020 A BR PI0906020A BR PI0906020 A2 BRPI0906020 A2 BR PI0906020A2
Authority
BR
Brazil
Prior art keywords
indazol
piperidin
carboxamide
phenyl
treatment
Prior art date
Application number
BRPI0906020-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jennifer R Foley
Robert Darrin Wilson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40404013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0906020(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BRPI0906020A2 publication Critical patent/BRPI0906020A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
BRPI0906020-0A 2008-01-08 2009-01-08 Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento BRPI0906020A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1033308P 2008-01-08 2008-01-08
PCT/GB2009/000041 WO2009087381A1 (en) 2008-01-08 2009-01-08 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide

Publications (1)

Publication Number Publication Date
BRPI0906020A2 true BRPI0906020A2 (pt) 2015-06-30

Family

ID=40404013

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906020-0A BRPI0906020A2 (pt) 2008-01-08 2009-01-08 Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento

Country Status (16)

Country Link
US (1) US8436185B2 (OSRAM)
EP (1) EP2240466B1 (OSRAM)
JP (1) JP5989965B2 (OSRAM)
KR (1) KR101653548B1 (OSRAM)
CN (2) CN101932572A (OSRAM)
AU (1) AU2009203598B2 (OSRAM)
BR (1) BRPI0906020A2 (OSRAM)
CA (1) CA2711491C (OSRAM)
ES (1) ES2548131T3 (OSRAM)
FR (1) FR18C1020I2 (OSRAM)
IL (1) IL206201A (OSRAM)
MX (1) MX337421B (OSRAM)
NL (1) NL300938I2 (OSRAM)
NZ (1) NZ586675A (OSRAM)
WO (1) WO2009087381A1 (OSRAM)
ZA (1) ZA201003902B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
WO2010111063A1 (en) 2009-03-21 2010-09-30 Ning Xi Amino ester derivatives, salts thereof and methods of use
JP5745283B2 (ja) 2010-02-12 2015-07-08 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
WO2014088983A1 (en) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
KR20170016498A (ko) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
IL283006B2 (en) 2015-04-01 2023-10-01 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
WO2017056498A1 (ja) * 2015-09-30 2017-04-06 国立大学法人東北大学 糖尿病性腎症の判定マーカー
PT3478286T (pt) 2016-06-29 2024-01-31 Tesaro Inc Métodos de tratamento do cancro do ovário
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
CN107663190B (zh) * 2016-07-29 2020-06-09 钟桂发 一种尼拉帕尼及其中间体的制备方法以及中间体化合物
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
EP3689419A1 (en) 2016-11-01 2020-08-05 AnaptysBio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
WO2018183354A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
EP3606523A1 (en) * 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
US11384062B2 (en) 2017-04-04 2022-07-12 Combiphos Catalysts, Inc. Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
AU2018258274C1 (en) 2017-04-24 2021-12-02 Tesaro, Inc. Methods of manufacturing of niraparib
KR102769634B1 (ko) 2017-04-27 2025-02-19 테사로, 인코포레이티드 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) * 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
CN108530425A (zh) * 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
US10927095B2 (en) 2017-08-14 2021-02-23 Teva Pharmaceuticals International Gmbh Processes for the preparation of Niraparib and intermediates thereof
US20200271666A1 (en) * 2017-09-13 2020-08-27 B.R.A.H.M.S Gmbh Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
WO2019053116A1 (en) * 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh FLUID THERAPY GUIDING METHOD BASED ON PROADRENOMEDULLINE
US20200264199A1 (en) * 2017-09-13 2020-08-20 B.R.A.H.M.S Gmbh Pct and pro-adm as markers for monitoring antibiotic treatment
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
MX2020003799A (es) * 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.
WO2019133697A1 (en) 2017-12-27 2019-07-04 Tesaro, Inc. Methods of treating cancer
EP3749352A1 (en) 2018-02-05 2020-12-16 Tesaro Inc. Pediatric niraparib formulations and pediatric treatment methods
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
CN118994103A (zh) * 2018-10-03 2024-11-22 特沙诺有限公司 尼拉帕利盐
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
WO2020072860A1 (en) * 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
WO2020225753A2 (en) 2019-05-06 2020-11-12 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN110407704B (zh) * 2019-08-19 2022-05-17 常州沃腾化工科技有限公司 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法
MX2022014003A (es) 2020-05-08 2022-11-30 Janssen Pharmaceutica Nv Tratamientos del cancer de prostata con combinaciones de acetato de abiraterona y niraparib.
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
EP4472634A1 (en) 2022-02-04 2024-12-11 JANSSEN Pharmaceutica NV Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
WO2023159066A1 (en) 2022-02-15 2023-08-24 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
WO2024238587A1 (en) 2023-05-17 2024-11-21 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer
WO2025027138A1 (en) 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
CN117843713A (zh) * 2023-12-18 2024-04-09 上海亲合力生物医药科技股份有限公司 基于肿瘤微环境激活的激酶抑制剂、组合物及应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
JPH11510154A (ja) * 1995-08-02 1999-09-07 ニューキャッスル ユニバーシティ ベンチャーズ リミテッド ベンズイミダゾール化合物
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
EP1124805B1 (de) 1998-10-30 2003-05-21 Lonza AG Verfahren zur herstellung von 4-[(2',5'-diamino-6'-halogenpyrimidin-4'-yl)amino]-cyclopent-2-enylmethanolen
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
RU2001116581A (ru) 1998-11-17 2004-02-20 БАСФ Акциенгезельшафт (DE) Замещенные 2-фенилбензимидазолы и 2-фенилиндолы, их получение и применение
RU2001117757A (ru) * 1998-11-27 2004-02-27 БАСФ Акциенгезельшафт (DE) Замещенные бензимидазолы и их применение в качестве ингибиторов поли(аденозиндифосфатрибоза)полимеразы
DE19918211A1 (de) * 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
US6508365B1 (en) * 1999-12-28 2003-01-21 Pitney Bowes Inc. Method of removing mail from a mailstream using an incoming mail sorting apparatus
AU2001240542A1 (en) * 2000-02-01 2001-08-14 Basf Aktiengesellschaft Heterocyclic compounds and their use as parp inhibitors
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2002068407A1 (en) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole compound
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003062234A1 (en) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Quinoxaline compounds
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004014861A1 (ja) 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キノリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
CN1852893A (zh) * 2003-07-21 2006-10-25 史密丝克莱恩比彻姆公司 (2S,4S)－4－氟－1－[4－氟－β－(4－氟苯基)－L－苯基丙氨酰基]－2－吡咯烷甲腈对甲苯磺酸盐及其无水晶体形式
WO2005047290A2 (en) * 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
WO2005066136A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Bicyclic derivatives as ppar modulators
KR100876520B1 (ko) 2004-09-22 2008-12-31 화이자 인코포레이티드 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006110683A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva
ES2378692T3 (es) 2005-09-29 2012-04-17 Abbott Laboratories Las 1H-benzimidazol-4-carboxamidas sustituidas con fenilo en la posición 2 son potentes inhibidores de PARP
EP1966157B1 (en) * 2005-11-15 2010-03-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
JP4611441B2 (ja) * 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
ATE553104T1 (de) * 2006-05-02 2012-04-15 Abbott Lab Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US7892667B2 (en) * 2006-09-13 2011-02-22 Altek Corporation Battery security device
RS51780B (sr) * 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
JP2008228154A (ja) * 2007-03-15 2008-09-25 Fujitsu Ltd 表示装置，および遠隔操作装置

Also Published As

Publication number Publication date
JP5989965B2 (ja) 2016-09-07
RU2495035C2 (ru) 2013-10-10
WO2009087381A1 (en) 2009-07-16
RU2010133241A (ru) 2012-02-20
KR101653548B1 (ko) 2016-09-02
US20100286203A1 (en) 2010-11-11
US8436185B2 (en) 2013-05-07
EP2240466B1 (en) 2015-07-29
CA2711491A1 (en) 2009-07-16
MX337421B (es) 2016-03-04
CN101932572A (zh) 2010-12-29
FR18C1020I2 (fr) 2019-06-07
AU2009203598B2 (en) 2013-09-26
AU2009203598A1 (en) 2009-07-16
MX2010006593A (es) 2010-12-21
KR20100114021A (ko) 2010-10-22
FR18C1020I1 (OSRAM) 2018-07-13
IL206201A0 (en) 2010-12-30
CA2711491C (en) 2016-03-08
IL206201A (en) 2014-07-31
JP2011509252A (ja) 2011-03-24
ZA201003902B (en) 2011-02-23
EP2240466A1 (en) 2010-10-20
NZ586675A (en) 2012-04-27
CN106008460B (zh) 2022-08-12
CN106008460A (zh) 2016-10-12
ES2548131T3 (es) 2015-10-14
NL300938I2 (nl) 2019-01-08

Similar Documents

Publication Publication Date Title
BRPI0906020A2 (pt) Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento
NO2022018I1 (no) Avacopan samt farmaceutisk acceptable salte deraf
NL301176I2 (nl) Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan
NO2017033I1 (no) baricitinib og farmasøytisk akseptable salter derav
NL300891I2 (nl) Lotilaner en zouten daarvan
FI20085839A0 (fi) Menetelmiä ja välineitä pehmytkudosteknologiaan
PT2534153T (pt) Sais e polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
BRPI0905952A2 (pt) Composto e sais do mesmo e compição farmacêutica
BRPI0821858A2 (pt) Composto, composição para cuidado oral, e, método
DK3216793T3 (da) Triazinforbindelser som p13-kinase- og mtor-inhibitorer
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
BRPI0822825A2 (pt) Implemento para cuidado oral, e, método para formar um implemento para cuidado oral
NO2016014I2 (no) ceritinib eller farmasøytisk akseptable salter derav
BRPI0919626A2 (pt) implante dental
BRPI0817923A2 (pt) Implemento para cuidado oral, e, método
BRPI0918492A2 (pt) uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0913293A2 (pt) método para inibir a formação de uma biopelícula, composição farmacêutica tópica, rinsagem cirúrgica, bandagem, composição de limpeza, e, rinsagem dental.
BRPI0907109A2 (pt) lenço dental e método
BRPI0909770A2 (pt) Vacina, e, kit
BRPI0919575A2 (pt) método, e, composição
NL301214I2 (nl) Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LIMITED (GB) , SCHERING CORP

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME LIMITED (GB) , MERCK SHARP A

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME LIMITED (GB) , MERCK SHARP A

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B15W Others matters related to applications: legal action concerning application

Free format text: INPI NO 52402.010273/2021-76 ORIGEM: 17A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1067890-21.2021.4.01.3400 NULIDADE DE ATO ADMINISTRATIVO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: MERCK SHARP AND DOHME LIMITED E MERCK SHARP AND DOHME CORP REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI

B15N Others concerning applications: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.010273/2021-76 PROCESSO: 1067890-21.2021.4.01.3400 L 17A VARA FEDERAL CIVEL DA SJDF AUTORAS: MERCK SHARP AND DOHME LIMITED E MERCK SHARP AND DOHME CORP. REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI SENTENCA: A VISTA DO EXPOSTO, PREJUDICADOS OS EMBARGOS DE DECLARACAO ANTERIORMENTE OPOSTOS PELA PARTE AUTORA, JULGO PROCEDENTE A DEMANDA, DANDO POR EXTINTO O PROCESSO COM RESOLUCAO DO MERITO, PARA DECLARAR A NULIDADE DOS ATOS DE INTIMACAO RELATIVOS AO PARECER TECNICO DE NAO PATENTEABILIDADE, A DECISAO DE INDEFERIMENTO E A DECISAO DE MANUTENCAO DO INDEFERIMENTO, TODOS ELES PRATICADOS PELA AUTARQUIA RE NO BOJO DO SEU PEDIDO DE PATENTE PI0906020-0.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: POR DETERMINACAO JUDICIAL, CONFORME PROCESSO NO 1071712-13.2024.4.01.3400, ANULADA A PUBLICACAO CODIGO 9.2.4 NA RPI NO 2602 DE 17/11/2020 POR TER SIDO INDEVIDA.

B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.2 NA RPI NO 2588 DE 11/08/2020 POR TER SIDO INDEVIDA.

B153 Others concerning applications: republication [chapter 15.33 patent gazette]

Free format text: REF. AO DESPACHO 15.14 PUBLICADO NA RPI2726 DE 04/04/2023 ONDE SE LE O TEOR DA SENTENCA, CONSIDERE-SE O SEGUINTE TEXTO:"A VISTA DO EXPOSTO, DIANTE DAS SINGULARES CIRCUNSTANCIAS FATICAS QUE ENVOLVEM O CASO CONCRETO, COM ESTEIO NO ART. 487, INCISO I, DO CPC/2015, PREJUDICADOS OS EMBARGOS DE DECLARACAO ANTERIORMENTE OPOSTOS PELA PARTE AUTORA (FLS. 208/210), JULGO PROCEDENTE A DEMANDA, DANDO POR EXTINTO O PROCESSO COM RESOLUCAO DO MERITO, PARA (I) DECLARAR A NULIDADE DOS ATOS DE INTIMACAO RELATIVOS AO PARECER TECNICO DE NAO PATENTEABILIDADE, A DECISAO DE INDEFERIMENTO E A DECISAO DE MANUTENCAO DO INDEFERIMENTO, PRATICADOS NO BOJO DO SEU PEDIDO DE PATENTE PI0906020-0; BEM COMO PARA (II) CONDENAR

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]